Condition: Tachyarrhythmia · Sponsor: Medtronic
Medtronic is sponsoring the LEADR PAS to provide continuing evaluation and periodic reporting of safety and effectiveness of the OmniaSecure™ defibrillation lead following commercial release. The LEADR PAS is conducted within Medtronic's Product Surveillance Registry Platform (NCT01524276).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Stanford Hospital & Clinics | Stanford, California, United States | — |
| COR Healthcare | Torrance, California, United States | — |
| Childrens Hospital Colorado | Aurora, Colorado, United States | — |
| Hartford Hosptial | Hartford, Connecticut, United States | — |
| Childrens National Medical Center | Washington D.C., District of Columbia, United States | — |
| Heart Rhythm Solutions | Hollywood, Florida, United States | — |
| Cardiovascular Institute of Northwest Florida | Panama City, Florida, United States | — |
| Heart & Vascular Institute of Florida | Safety Harbor, Florida, United States | — |
| Intercoastal Medical Group | Sarasota, Florida, United States | — |
| University of South Florida Health (USF) | Tampa, Florida, United States | — |
| WellStar Research Institute | Marietta, Georgia, United States | — |
+ 61 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.